T. Cox

发表

Time-dependent ROC curve analysis in medical research: current methods and applications

R. Kolamunnage-Dona, A. Kamarudin, T. Cox, 2017, BMC Medical Research Methodology.

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

John R. Mackey, Fiona Campbell, David Goldstein, 2014, Journal of the National Cancer Institute.

A Robust Parameterization for Unbounded Covariates Within the Cox Proportional Hazards Model

R. Jackson, T. Cox, 2014 .

New‐Generation High‐Definition Colonoscopes Increase Adenoma Detection when Screening a Moderate‐Risk Population for Colorectal Cancer

T. Cox, C. Probert, S. Subramanian, 2017, Clinical colorectal cancer.

Incidence of Post-ERCP Pancreatitis From Direct Pancreatic Juice Collection in Hereditary Pancreatitis and Familial Pancreatic Cancer Before and After the Introduction of Prophylactic Pancreatic Stents and Rectal Diclofenac

W. Greenhalf, J. Neoptolemos, R. Sutton, 2015, Pancreas.

Diagnostic tools and strategies for assessing disease progression in Alkaptonuria

L. Ranganath, T. Cox, E. Psarelli, 2015 .

Management of large bowel obstruction with self‐expanding metal stents. A multicentre retrospective study of factors determining outcome

K. Bodger, J. Ramesh, T. Cox, 2014, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

What Is the Best Way to Identify Malignant Transformation Within Pancreatic IPMN: A Systematic Review and Meta-Analyses

J. Neoptolemos, R. Sutton, P. Ghaneh, 2015, Clinical and Translational Gastroenterology.

Testing the equivalence of survival distributions using PP- and PPP-plots

T. Cox, 2013, Trials.

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma

W. Greenhalf, Eithne Costello, J. Neoptolemos, 2016, British Journal of Cancer.

Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model

S. Berhane, H. Toyoda, P. Johnson, 2014, British Journal of Cancer.

Adjuvant therapy for pancreatic cancer.

J. Neoptolemos, P. Ghaneh, T. Cox, 1999, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

University of Birmingham Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma

W. Greenhalf, Eithne Costello, J. Neoptolemos, 2016 .

Bayesian analysis unravels pancreas-cancer adjuvant therapy.

J. Neoptolemos, T. Cox, 2013, The Lancet. Oncology.

Contents Vol. 11, 2011

E. Achten, J. Neoptolemos, D. Yadav, 2012, Pancreatology.

The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers

H. Reeves, P. Johnson, S. Berhane, 2013, Cancer Epidemiology, Biomarkers & Prevention.

GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer

N. Malats, F. Real, M. Büchler, 2016, Gut.

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

T. Hickish, W. Greenhalf, Eithne Costello, 2014, The Lancet. Oncology.

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.

M. Büchler, J. Neoptolemos, M. Lerch, 2012, JAMA.

Prediction of invasive candidal infection in critically ill patients with severe acute pancreatitis

A. Hall, C. Halloran, T. Cox, 2013, Critical Care.

Testing the Equivalence of Survival Distributions using PP- and PPP-Plots

T. Cox, 2014 .

Evidence of Adjuvant Chemotherapy of Ductal Pancreatic Cancer

J. Neoptolemos, P. Ghaneh, C. Halloran, 2015 .

A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.

W. Greenhalf, J. Neoptolemos, T. Roques, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.

M. Büchler, J. Neoptolemos, J. Izbicki, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer

M. Büchler, J. Mackey, W. Greenhalf, 2018, British Journal of Cancer.

The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma

J. Kleeff, M. Büchler, J. Neoptolemos, 2017, Annals of surgery.

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.

A. Pettitt, M. Pirmohamed, D. Catovsky, 2013, Blood.

Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.

M. Manns, T. Berg, P. Galle, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

fludarabine plus cyclophosphamide in chronic lymphocytic leukemia is an independent determinant of inferior response to CYP2B6*6

M. Pirmohamed, D. Catovsky, D. Carr, 2014 .

Partial Pancreatic Resection for Pancreatic Malignancy Is Associated with Sustained Pancreatic Exocrine Failure and Reduced Quality of Life: A Prospective Study

J. Neoptolemos, R. Sutton, P. Ghaneh, 2011, Pancreatology.

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.

T. Hickish, W. Greenhalf, Eithne Costello, 2017, The Lancet. Oncology.

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer

J. Mackey, W. Greenhalf, J. Neoptolemos, 2018, British Journal of Cancer.

Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria afte

Andrea Zatkova, Annalisa Santucci, Daniela Braconi, 2014, Annals of the rheumatic diseases.

Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.

J. Jarvis, L. Ranganath, B. Olsson, 2020, The lancet. Diabetes & endocrinology.

Subclinical ochronosis features in alkaptonuria: a cross-sectional study

M. Robinson, L. Ranganath, D. Giustarini, 2019, BMJ Innovations.

Natural history of alkaptonuria revisited: analyses based on scoring systems

L. Ranganath, T. Cox, 2011, Journal of Inherited Metabolic Disease.

Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy

M. Büchler, J. Mackey, W. Greenhalf, 2018, British Journal of Cancer.

Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus

D. Tuveson, I. Jacobs, U. Menon, 2015, Clinical Cancer Research.

Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease

W. Greenhalf, Eithne Costello, J. Neoptolemos, 2014, Molecular Cancer.

The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer

J. Kleeff, M. Büchler, W. Greenhalf, 2016, British Journal of Cancer.

Latent Class Modeling with A Time-To-Event Distal Outcome: A Comparison of One, Two and Three-Step Approaches

Marta García-Fiñana, D. Lythgoe, Trevor Cox, 2018, Structural Equation Modeling: A Multidisciplinary Journal.

Application of methods for central statistical monitoring in clinical trials

Allan Hackshaw, Trevor Cox, A. Hackshaw, 2013, Clinical trials.

The Value of Source Data Verification in a Cancer Clinical Trial

Catrin Tudur Smith, John P. Neoptolemos, Janet Dunn, 2012, PloS one.

HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials.

M. Büchler, J. Mackey, W. Greenhalf, 2013 .

O110 AN INTERNATIONAL COLLABORATIVE STUDY ASSESSING THE ROLE OF AETIOLOGY AND STAGE IN SURVIVAL IN HCC – IMPLICATIONS FOR SCREENING

B. Sangro, W. Yeo, P. Johnson, 2014 .

Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria.

L. Ranganath, B. Olsson, A. Milan, 2015, JIMD reports.

Dual-focus Magnification, High-Definition Endoscopy Improves Pathology Detection in Direct-to-Test Diagnostic Upper Gastrointestinal Endoscopy.

H. Smart, M. Burkitt, T. Cox, 2017, Journal of gastrointestinal and liver diseases : JGLD.

iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance

H. Friess, W. Greenhalf, Eithne Costello, 2013, British Journal of Cancer.

Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer.

I. Jacobs, U. Menon, A. Gentry-Maharaj, 2015, Journal of proteomics.

P554 ASSESSMENT OF PROGNOSIS IN HEPATOCELLULAR CARCINOMA USING A BIOMARKER BASED APPROACH: VALIDATION AND EXTENSION OF THE BALAD MODEL

P. Johnson, S. Berhane, H. Toyoda, 2014 .

Chemotherapy, radiotherapy, chemoradiotherapy and combination therapy in localised and locally advanced pancreatic cancer

J. Neoptolemos, P. Ghaneh, R. Jackson, 2014 .

Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater.

D. Smith, J. Neoptolemos, C. Bassi, 2011, Journal of Clinical Oncology.

Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria

L. Ranganath, A. Milan, T. Cox, 2019, Scientific reports.

Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice.

J. Jarvis, L. Ranganath, T. Cox, 2015, JIMD reports.

once daily nitisinone on 24-hour urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment

Martina, J. Jarvis, L. Ranganath, 2015 .

Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis

H. L. Wright, R. Moots, S. Edwards, 2017, Journal of leukocyte biology.

M. Büchler, J. Mackey, W. Greenhalf, 2018, British Journal of Cancer.

Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.

A. Milan, T. Cox, J. Harrold, 2018, Molecular genetics and metabolism.

M. Büchler, J. Neoptolemos, P. Ghaneh, 2011, Journal of Clinical Oncology.

The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma

J. Kleeff, M. Büchler, W. Greenhalf, 2016 .

A quantitative assessment of alkaptonuria

L. Ranganath, T. Cox, 2011, Journal of Inherited Metabolic Disease.

Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus

D. Tuveson, I. Jacobs, U. Menon, 2015, Clinical Cancer Research.

Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.

A. Milan, T. Cox, J. Harrold, 2018, Molecular genetics and metabolism.

Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria

A. Milan, T. Cox, J. Rovenský, 2019, Scientific Reports.